Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome

Journal of Clinical Gastroenterology

Volumn 47, Issue 7, 2013, Pages 602-607

  Tappenden, Kelly A ^a   Edelman, Jeffrey ^b   Joelsson, Bo ^c  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Christian Hospital   (United States)

^c NPS Pharmaceuticals Inc   (United States)

Author keywords

biopsy; crypt; dysplasia; villus

Indexed keywords

PLACEBO; TEDUGLUTIDE;

ARTICLE; COLITIS; COLLAGENOUS COLITIS; CONTROLLED STUDY; CROHN DISEASE; DYSPLASIA; EOSINOPHILIC COLITIS; HUMAN; HUMAN TISSUE; INTESTINAL FAILURE; INTESTINE BIOPSY; LARGE INTESTINE; LYMPHOCYTIC COLITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARENTERAL NUTRITION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; SHORT BOWEL SYNDROME; SMALL INTESTINE; SMALL INTESTINE MUCOSA; ULCERATIVE COLITIS;

ADAPTATION, PHYSIOLOGICAL; BIOPSY; COHORT STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; INTESTINE, LARGE; INTESTINE, SMALL; PARENTERAL NUTRITION; PEPTIDES; PROSPECTIVE STUDIES; SHORT BOWEL SYNDROME;

EID: 84880720595     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182828f57     Document Type: Article

References (33)

1. O'Keefe SJ, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4:6-10.
2. Buchman AL. The medical and surgical management of short bowel syndrome. Med Gen Med. 2004;6:12.
3. Buchman AL, Scolapio J, Fryer J. AGA technical review on short bowel syndrome and intestinal transplantation. Gastroenterology. 2003;124:1111-1134.
4. Drucker DJ, DeForest L, Brubaker PL. Intestinal response to growth factors administered alone or in combination with human [Gly2] glucagon-like peptide 2. Am J Physiol. 1997;273:G1252-G1262.
5. Yazbeck R, Howarth GS, Abbott CA. Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward? Cytokine Growth Factor Rev. 2009;20:175-184.
6. Dahly EM, Gillingham MB, Guo Z, et al. Role of luminal nutrients and endogenous GLP-2 in intestinal adaptation to mid-small bowel resection. Am J Physiol Gastrointest Liver Physiol. 2003;284:G670-G682.
7. Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut. 2002;50:428-435.
8. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr. 2006;26:391-411.
9. Koopmann MC, Nelson DW, Murali SG, et al. Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. JPEN J Parenter Enteral Nutr. 2008;32:254-265.
10. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2004;286:G964-972.
11. Guan X, Stoll B, Lu X, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology. 2003;125:136-147.
12. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806-815.
13. Baggio LL, Drucker DJ. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Pract Res Clin Endocrinol Metab. 2004;18:531-554.
14. Hartmann B, Johnsen AH, Orskov C, et al. Structure, measurement, and secretion of human glucagon-like peptide-Peptides. 2000;21:73-80.
15. Marier JF, Beliveau M, Mouksassi MS, et al. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48:1289-1299.
16. Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000;47:112-119.
17. Scott RB, Kirk D, MacNaughton WK, et al. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol. 1998;275:G911-921.
18. Sigalet DL, Martin GR. Hormonal therapy for short bowel syndrome. J Pediatr Surg. 2000;35:360-363; discussion 364.
19. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224-1231.
20. O'Keefe SJD, Jeppesen PB, Gilroy R, et al. Safety and Efficacy of Teduglutide after 52 weeks of treatment in patients with short bowel syndrome-intestinal failure. Clin Gastroenterol Hepatol. 2013. In Press.
21. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60:902-914.
22. Latt SA, Stetten G. Spectral studies on 33258 Hoechst and related bisbenzimidazole dyes useful for fluorescent detection of deoxyribonucleic acid synthesis. J Histochem Cytochem. 1976;24:24-33.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
24. Aperio ePathology Solutions. Scanscope CS System. Available at: http://www.aperio.com/pathology-services/scanscope-CSsystem- slides.asp. Accessed March 20, 2012.
25. Pascal RR. Dysplasia and early carcinoma in inflammatory bowel disease and colorectal adenomas. Hum Pathol. 1994;25:1160-1171.
26. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983;14: 931-968.
27. Tsai CH, Hill M, Asa SL, et al. Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol. 1997;273:E77-84.
28. Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2-current applications and future directions. Aliment Pharmacol Ther. 2007;25:365-372.
29. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001;61:687-693.
30. Chance WT, Sheriff S, Foley-Nelson T, et al. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer. 2000;37:215-222.
31. Thulesen J, Hartmann B, Hare KJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut. 2004;53:1145-1150.
32. Iakoubov R, Lauffer LM, Trivedi S, et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology. 2009;150: 4033-4043.
33. Koehler JA, Harper W, Barnard M, et al. Glucagonlike peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res. 2008;68: 7897-7904.